ASPOFAFF :: Journal - Volume 2 :: Volume 2 - Issue 1 :: Vol 2 - Iss 1 - Short Communication - Risperidone Utilization in Serious Bipolar Mood Disorders


	Home


	Shopping Cart


	Contact Us


	IRBD.ORG


	EUBF.ORG

All Enquiries:: +44 (0)20 8487 1421

Search:

Advanced search

Printable version

Categories

Help

ASPOFAFF :: Journal - Volume 2 :: Volume 2 - Issue 1 :: Vol 2 - Iss 1 - Short Communication - Risperidone Utilization in Serious Bipolar Mood Disorders

Vol 2 - Iss 1 - Short Communication - Risperidone Utilization in Serious Bipolar Mood Disorders #77

Risperidone Utilization in Serious Bipolar Mood Disorders

G.Tavormina
"Psychiatric Studies Centre", Piazza Portici, 11 - 2505 Provaglio di Iseo (BS) – Italy. E-mail: president@censtupsi.org

Objectives: To assess Risperidone utilization and utility, and its safety and tolerability too, in serious bipolar spectrum mood disorders.

Materials and Methods: A total of 18 outpatients were included in this open-label, non-comparative, naturalistic study, meeting DSM-IV diagnostic criteria for bipolar mood disorders. These diseases were assessed: Bipolar Mood Disorder (type II), Bipolar Mood Disorder (type mixed), Cyclothymic Disorders. Risperidone treatment was a subsequent additional therapy to mood-stabilizers and antidepressants. "GAS" Scale was adopted in determining the effects of Risperidone treatment before beginning therapy, after eight weeks of mood-stabilizers and antidepressants therapy, and after six weeks of Risperidone treatment. Risperidone treatment was an additional therapy in combination with mood-stabilizers and antidepressants to obtain the optimum mood balance conditions. Tolerability was assessed by registering treatment-emergent adverse events.

Results: In beginning of therapy, all the patients obtained with the "GAS" a score lower than 35 points; after the eight weeks of therapy with mood-stabilizers and antidepressants the patients obtained with the "GAS" a score between 55 and 75 points. After the additional therapy with Risperidone, after others six weeks valuation, all the patients obtained with the "GAS" more than 85 points.

Tolerability: Only 17% of the patients had to stop the treatment, after the six weeks valuation, for not transient side effects (EPS; endocrine).

Conclusion: In this naturalistic study Risperidone demonstrated its considerable efficacy in serious bipolar spectrum mood disorder as add-on therapy to mood stabilizers and antidepressants, and also its safety and tolerability.

References:
Akiskal HS. The prevalent clinical spectrum of bipolar disorders: beyond DSM-IV. J Clin Psychopharmacol 1996; 16 (suppl 1): 4-14.
Koukopulos A, Caliari B, Tundo A, Minnai G, Floris G, Reginaldi D, Tondo L. Rapid cyclers, temperament and antidepressants. Comp Psychiatry 1983; 24: 249-58.
Sachs GS. Bipolar mood disorder: practical strategies for acute and maintenance phase treatment. J Clin Psychopharmacol 1996; 16 (suppl 1): 32S-47S.

Details

Price: €0.01

Options

Quantity

Add to cart

Send to friend

Your name: *

Your e-mail: *

Recipient's e-mail: *

Send to friend

Your cart

	Cart is empty

View cart
Checkout

Authentication

Username

Password

Recover password

If Javascript is disabled in your browser click here